Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.

Biotechnology • Healthcare • Boston, MA, United States • TRDA (NGM)

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

857 520 9158 One Design Center Place, Boston, MA 02210, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Yahoo Finance • Nov 6
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha
Seeking Alpha • Nov 17
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - Sahm
Sahm • Dec 19
Entrada lays off 20% of staff weeks after having FDA hold lifted - Fierce Biotech
Fierce Biotech • Apr 30
5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k - Investing.com
Investing.com • Jul 11

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Entrada Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Entrada Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Entrada Therapeutics, Inc. have?
Entrada Therapeutics, Inc. has approximately 183 employees.
What industry is Entrada Therapeutics, Inc. in?
Entrada Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Entrada Therapeutics, Inc. a publicly traded company?
Yes, Entrada Therapeutics, Inc. is publicly traded under the ticker symbol TRDA on the NGM. The company has a market capitalization of approximately $0.39 billion.
Where is Entrada Therapeutics, Inc. headquartered?
Entrada Therapeutics, Inc. is headquartered in Boston, MA, United States at One Design Center Place, Boston, MA 02210, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.